z-logo
Premium
Statins for the prevention and treatment of acute lung injury and acute respiratory distress syndrome: A systematic review and meta‐analysis
Author(s) -
Xiong Bo,
Wang Chunbin,
Tan Jie,
Cao Yin,
Zou Yanke,
Yao Yuanqing,
Qian Jun,
Rong Shunkang,
Huang Yuwen,
Huang Jing
Publication year - 2016
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/resp.12820
Subject(s) - medicine , ards , randomized controlled trial , relative risk , intensive care unit , meta analysis , cohort study , cohort , intensive care medicine , lung , confidence interval
The purpose of this meta‐analysis was to assess whether statins could reduce the morbidity of acute lung injury and acute respiratory distress syndrome (ALI/ARDS) in high‐risk patients and improve the clinical outcomes of patients with ALI/ARDS. Studies were obtained from PubMed, Medline, Embase and Cochrane Central Register of Controlled Trials. Randomized controlled trials (RCTs) and cohort studies, which reported morbidity, mortality, ventilator‐free days, length of stay in intensive care unit and hospital or oxygenation index, were included in our meta‐analysis. Risk ratio (RR) and weighted mean difference (WMD) were calculated using fixed or random effect model. A total of 13 studies covering 12 145 patients were included. Both the only RCT ( P  = 0.10) and cohort studies (RR, 1.02; 95% CI, 0.67 to 1.55; P  = 0.94) showed that statin therapy did not lower the morbidity of ALI/ARDS in high‐risk patients. The mortality of ALI/ARDS patients was less likely to be improved by statins (RCT, RR, 1.00; 95% CI, 0.84 to 1.20; P  = 0.97; cohort studies, RR, 1.04; 95% CI, 0.85 to 1.27; P  = 0.72). Moreover, no significant difference was observed in ventilator‐free days, length of stay in intensive care unit as well as hospital and oxygenation index. This meta‐analysis suggests that statins neither provide benefit for lowering the morbidity of ALI/ARDS in high‐risk patients nor improve the clinical outcomes of ALI/ARDS patients. Hence, it may not be appropriate to advocate statin use for the prevention and treatment of ALI/ARDS.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here